Delayed or impaired wound healing significantly reduces the overall life-quality of affected patients and causes a great burden to the healthcare system.Recently,mesenchymal stem cell(MSC)-derived extracellular vesicl...Delayed or impaired wound healing significantly reduces the overall life-quality of affected patients and causes a great burden to the healthcare system.Recently,mesenchymal stem cell(MSC)-derived extracellular vesicles(MSC-EVs)have been demonstrated to hold great promise for wound healing due to their rich cargo of bioactive substances.Through the transfer of these bioactive substances to recipient cells in the wound area,MSC-EVs can promote angiogenesis,modulate immune responses,and reduce inflammation,which are integral components of the wound healing process.The inherent therapeutic effects of MSC-EVs largely depend on their cargo,which consists of microRNAs,proteins,lipids,and other bioactive compounds.While numerous studies have extensively assessed the efficacy of MSC-EVs in preclinical animal models,only a few have advanced to clinical trials.For example,Aegle Therapeutics aimed to investigate the safety and efficacy of bone marrow MSC-EVs for patients with deep seconddegree skin burns,with wound healing potential assessed by recording the percentage of re-epithelialization and time to complete closure over an 8-week period(ClinicalTrials.gov Identifier NCT05078385).Another clinical trial(ClinicalTrials.gov Identifier NCT05243368)sought to evaluate the effects of personalized nutritional interventions combined with MSC-EVs on the regenerative capacity and wound healing of skin ulcers in diabetic patients.Although preclinical investigations of MSC-EVs in wound healing have yielded promising results,the translation to clinical settings is in its early stages.Future research should incorporate sophisticated and varied clinical trial designs to thoroughly assess thesafety and efficacy of MSC-EVs.展开更多
基金the CAMS Innovation Fund for Medical Sciences(2022-I2M-1-012)。
文摘Delayed or impaired wound healing significantly reduces the overall life-quality of affected patients and causes a great burden to the healthcare system.Recently,mesenchymal stem cell(MSC)-derived extracellular vesicles(MSC-EVs)have been demonstrated to hold great promise for wound healing due to their rich cargo of bioactive substances.Through the transfer of these bioactive substances to recipient cells in the wound area,MSC-EVs can promote angiogenesis,modulate immune responses,and reduce inflammation,which are integral components of the wound healing process.The inherent therapeutic effects of MSC-EVs largely depend on their cargo,which consists of microRNAs,proteins,lipids,and other bioactive compounds.While numerous studies have extensively assessed the efficacy of MSC-EVs in preclinical animal models,only a few have advanced to clinical trials.For example,Aegle Therapeutics aimed to investigate the safety and efficacy of bone marrow MSC-EVs for patients with deep seconddegree skin burns,with wound healing potential assessed by recording the percentage of re-epithelialization and time to complete closure over an 8-week period(ClinicalTrials.gov Identifier NCT05078385).Another clinical trial(ClinicalTrials.gov Identifier NCT05243368)sought to evaluate the effects of personalized nutritional interventions combined with MSC-EVs on the regenerative capacity and wound healing of skin ulcers in diabetic patients.Although preclinical investigations of MSC-EVs in wound healing have yielded promising results,the translation to clinical settings is in its early stages.Future research should incorporate sophisticated and varied clinical trial designs to thoroughly assess thesafety and efficacy of MSC-EVs.
